Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp irst-generation polymer-based sirolimus (Cypher) and paclitaxel (Taxus) drug-eluting stents (DES) have remarkably reduced angiographic restenosis and target lesion revascularization (TLR) by reducing neointimal hyperplasia compared with bare-metal stents (BMS). 1,2 Concern about vasculo-toxic effects, however, remains to be resolved. Previous case reports and observational studies showed that late and very late stent thrombosis occurred after DES implantation. 3, 4 As the main mechanisms of late and very late stent thrombosis, delayed arterial healing (persistent fibrin deposition and delayed re-endothelialization) due to drugs in DES, 5-9 and chronic inflammation and hypersensitivity reaction due to drugs and/or durable polymers in DES have been reported in animal and human pathology studies. 7-12 These studies noted enhanced inflammatory responses consisting predominantly of T lymphocytes and eosinophils around the stent struts and stent malapposition with vessel enlargement after DES implantation. 7,10-12 In clinical practice, previous intravascular ultrasound (IVUS) in vivo showed that positive coronary arterial remodeling after first-generation DES was associated with late restenosis and very late stent thrombosis. Those studies reported that positive Background: Out-stent plaque characteristics and eosinophilic inflammatory response, which correlates with positive remodeling after first-generation drug-eluting stent implantation, may be associated with late restenosis and very late stent thrombosis. The differences of out-stent plaque characteristics were compared between paclitaxeleluting stents (PES) and zotarolimus-eluting stents (ZES), using integrated backscatter-intravascular ultrasound (IB-IVUS).